Amphastar Pharmaceuticals, Inc. (AMPH) Rating Lowered to Sell at ValuEngine
ValuEngine lowered shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) from a hold rating to a sell rating in a research note released on Tuesday morning.
Other equities analysts have also recently issued research reports about the company. TheStreet raised Amphastar Pharmaceuticals from a c rating to a b- rating in a research note on Monday, June 26th. Jefferies Group LLC reaffirmed a buy rating and set a $19.00 target price (down previously from $20.00) on shares of Amphastar Pharmaceuticals in a research note on Friday, August 11th. Wells Fargo & Company reaffirmed a buy rating on shares of Amphastar Pharmaceuticals in a research note on Saturday, July 22nd. Piper Jaffray Companies set a $20.00 target price on Amphastar Pharmaceuticals and gave the company a buy rating in a research note on Saturday, July 29th. Finally, BMO Capital Markets reaffirmed a hold rating and set a $16.00 target price on shares of Amphastar Pharmaceuticals in a research note on Monday, July 31st. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average price target of $19.86.
Amphastar Pharmaceuticals (NASDAQ AMPH) opened at 15.55 on Tuesday. The stock has a 50 day moving average of $16.54 and a 200 day moving average of $15.87. The stock has a market capitalization of $718.33 million, a P/E ratio of 201.95 and a beta of 1.65. Amphastar Pharmaceuticals has a 1-year low of $12.05 and a 1-year high of $21.75.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Wednesday, August 9th. The company reported $0.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.05. Amphastar Pharmaceuticals had a return on equity of 2.42% and a net margin of 1.61%. The firm had revenue of $65.20 million for the quarter, compared to analysts’ expectations of $63.40 million. During the same quarter last year, the business posted $0.23 EPS. Amphastar Pharmaceuticals’s revenue was down 4.1% on a year-over-year basis. On average, analysts expect that Amphastar Pharmaceuticals will post $0.27 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Amphastar Pharmaceuticals, Inc. (AMPH) Rating Lowered to Sell at ValuEngine” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/26/amphastar-pharmaceuticals-inc-amph-rating-lowered-to-sell-at-valuengine.html.
Amphastar Pharmaceuticals announced that its board has authorized a stock buyback program on Wednesday, August 9th that authorizes the company to repurchase $20.00 million in shares. This repurchase authorization authorizes the company to purchase up to 2.8% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board believes its shares are undervalued.
In related news, Director Richard K. Prins sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $14.80, for a total value of $74,000.00. Following the completion of the sale, the director now directly owns 33,844 shares in the company, valued at approximately $500,891.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jason B. Shandell sold 11,482 shares of the business’s stock in a transaction that occurred on Wednesday, May 31st. The stock was sold at an average price of $16.92, for a total value of $194,275.44. Following the completion of the sale, the director now owns 241,342 shares of the company’s stock, valued at $4,083,506.64. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 51,482 shares of company stock valued at $842,225. Corporate insiders own 11.10% of the company’s stock.
A number of large investors have recently bought and sold shares of the company. Teachers Advisors LLC raised its stake in Amphastar Pharmaceuticals by 0.3% in the fourth quarter. Teachers Advisors LLC now owns 542,953 shares of the company’s stock valued at $10,001,000 after buying an additional 1,693 shares during the period. Louisiana State Employees Retirement System raised its position in shares of Amphastar Pharmaceuticals by 1.4% in the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the company’s stock worth $212,000 after buying an additional 200 shares during the period. Boston Advisors LLC raised its position in shares of Amphastar Pharmaceuticals by 21.9% in the first quarter. Boston Advisors LLC now owns 37,340 shares of the company’s stock worth $541,000 after buying an additional 6,700 shares during the period. Fisher Asset Management LLC raised its position in shares of Amphastar Pharmaceuticals by 52.1% in the first quarter. Fisher Asset Management LLC now owns 151,055 shares of the company’s stock worth $2,190,000 after buying an additional 51,731 shares during the period. Finally, Great West Life Assurance Co. Can raised its position in shares of Amphastar Pharmaceuticals by 13.0% in the first quarter. Great West Life Assurance Co. Can now owns 50,874 shares of the company’s stock worth $738,000 after buying an additional 5,841 shares during the period. Hedge funds and other institutional investors own 43.83% of the company’s stock.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Stock Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.